GABINET LEKARSKI MALGORZATA SARYUSZ-WOLSKA
- Address
- lock Available on a paid plan
Diabetes Management
The site focuses on type 2 diabetes and type 1 diabetes within the broader field of nutritional and metabolic diseases. Trials aim to evaluate new weekly insulin‑semaglutide combinations and weekly insulin formulations to improve glycaemic control and simplify treatment.
- Weekly insulin‑semaglutide combo for better HbA1c
- Once‑weekly insulin icodec versus daily insulin glargine
- Combination therapy with insulin aspart
- Non‑inferiority and superiority assessments
These studies seek to reduce injection frequency, enhance blood‑sugar stability, and offer patients more convenient therapeutic options.
Obesity & Kidney Health
Research also targets chronic kidney disease in people with overweight or obesity and type 2 diabetes, falling under the nutritional and metabolic diseases therapeutic area. The goal is to test novel agents that may slow kidney‑disease progression and promote weight loss.
- CagriSema impact on kidney disease markers
- Comparative study of CagriSema versus cagrilintide and placebo
- Weight‑loss efficacy of NNC0487‑0111 versus semaglutide
- Surrogate endpoints for renal function
By addressing both metabolic control and renal outcomes, the trials aim to improve long‑term health for patients struggling with obesity‑related kidney risk.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Novo Nordisk A/S1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novo Nordisk A/S4trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in GABINET LEKARSKI MALGORZATA SARYUSZ-WOLSKA
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 40-Week Randomized Study Evaluating the Efficacy and Safety of Weekly Insulin Icodec/Semaglutide Versus Daily Insulin Glargine in Type 2 Diabetes Patients | Novo Nordisk A/S | Phase III | Not Recruiting | Feb 2024 | Jun 2025 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Semaglutide | 3 | Unknown | 2024-02-07 | 2026-05-27 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.